San Diego’s HUYA Bioscience International announced Thursday that it has appointed Dr. Dmitri Kharkevitch to vice president of clinical development oncology.
Bringing Kharkevitch on board is part of the company’s expansion of its clinical development programs for its lead anti-cancer drug, HBI-8000, according to a HUYA news release.
Kharkevitch brings over 30 years of experience in oncology to the table, including 15 years in positions with Big Pharma and biotech, including positions at Roche, Pfizer, Bristol-Myers Squibb, and Vical.
He has over 60 publications and patents that complement HUYA’s expertise in immuno-oncology, and his international regulatory experience includes Investigational New Drug and New Drug Application submissions to both the U.S. Food and Drug Administration and European Medicines Agency, according to the release.
Educated in Moscow, Russia, Kharkevitch received his medical and doctoral degrees from N.I. Pirogov Medical School and N.N. Blokhin Cancer Center.
HUYA, which develops biopharmaceuticals for cancer and cardiovascular indications, has offices in the United Kingdom, Japan and eight locations across China, with joint headquarters in San Diego and Shanghai.
